APO RESEARCH · REPORT
Transforming Growth Factor Beta 1
Transforming growth factor beta 1 or TGF-β1 is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation, and apoptosis. In humans, TGF-β1 is encoded by the TGFB1 gene
Product & engineering
Understand the product.
Transforming growth factor beta 1 or TGF-β1 is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation, and apoptosis. In humans, TGF-β1 is encoded by the TGFB1 gene
Selected research
Industry Research
Transforming Growth Factor Beta 1 Industry Research Report 2026
Market perspective
Transforming growth factor beta 1 or TGF-β1 is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation, and apoptosis. In humans, TGF-β1 is encoded by the TGFB1 gene
North America is the largest Transforming Growth Factor Beta 1 market with about 69% market share. Europe is follower, accounting for about 16% market share.The key manufacturers are Roche, Shionogi Ltd, Acceleron Pharma Inc, Genzyme Corp, Isarna Therapeutics GmbH, Scholar Rock, Sirnaomics Inc, Eli Lilly and Co, Formation Biologics Inc, Novartis AG etc.
Report Scope
Read the full market overview
This report quantifies the global Transforming Growth Factor Beta 1 market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Transforming Growth Factor Beta 1 Market by Company
Roche
Shionogi Ltd
Acceleron Pharma Inc
Genzyme Corp
Isarna Therapeutics GmbH
Scholar Rock
Sirnaomics Inc
Eli Lilly and Co
Formation Biologics Inc
Novartis AG
Transforming Growth Factor Beta 1 Segment by Type
Pirfenidone
Galunisertib
Others
Transforming Growth Factor Beta 1 Segment by Application
IPF
Cancer
Others
Transforming Growth Factor Beta 1 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transforming Growth Factor Beta 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transforming Growth Factor Beta 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transforming Growth Factor Beta 1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Transforming Growth Factor Beta 1 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Transforming Growth Factor Beta 1 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Transforming Growth Factor Beta 1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pirfenidone
- Galunisertib
- Others
Applications
- IPF
- Cancer
- Others
Companies covered
- Roche
- Shionogi Ltd
- Acceleron Pharma Inc
- Genzyme Corp
- Isarna Therapeutics GmbH
- Scholar Rock
- Sirnaomics Inc
- Eli Lilly and Co
- Formation Biologics Inc
- Novartis AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Transforming Growth Factor Beta 1 Market Size (2021-2032)
- 2.2.2 Global Transforming Growth Factor Beta 1 Sales (2021-2032)
- 2.2.3 Global Transforming Growth Factor Beta 1 Market Average Price (2021-2032)
- 2.3 Transforming Growth Factor Beta 1 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Pirfenidone
- 2.3.3 Galunisertib
- 2.3.4 Others
- 2.4 Transforming Growth Factor Beta 1 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 IPF
- 2.4.3 Cancer
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Transforming Growth Factor Beta 1 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Transforming Growth Factor Beta 1 Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Transforming Growth Factor Beta 1 Revenue of Manufacturers (2021-2026)
- 3.4 Global Transforming Growth Factor Beta 1 Average Price by Manufacturers (2021-2026)
- 3.5 Global Transforming Growth Factor Beta 1 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Transforming Growth Factor Beta 1, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Transforming Growth Factor Beta 1, Product Type & Application
- 3.8 Global Manufacturers of Transforming Growth Factor Beta 1, Established Date
- 3.9 Global Transforming Growth Factor Beta 1 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Roche
- 4.1.1 Roche Company Information
- 4.1.2 Roche Business Overview
- 4.1.3 Roche Transforming Growth Factor Beta 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Roche Transforming Growth Factor Beta 1 Product Portfolio
- 4.1.5 Roche Recent Developments
- 4.2 Shionogi Ltd
- 4.2.1 Shionogi Ltd Company Information
- 4.2.2 Shionogi Ltd Business Overview
- 4.2.3 Shionogi Ltd Transforming Growth Factor Beta 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shionogi Ltd Transforming Growth Factor Beta 1 Product Portfolio
- 4.2.5 Shionogi Ltd Recent Developments
- 4.3 Acceleron Pharma Inc
- 4.3.1 Acceleron Pharma Inc Company Information
- 4.3.2 Acceleron Pharma Inc Business Overview
- 4.3.3 Acceleron Pharma Inc Transforming Growth Factor Beta 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Acceleron Pharma Inc Transforming Growth Factor Beta 1 Product Portfolio
- 4.3.5 Acceleron Pharma Inc Recent Developments
- 4.4 Genzyme Corp
- 4.4.1 Genzyme Corp Company Information
- 4.4.2 Genzyme Corp Business Overview
- 4.4.3 Genzyme Corp Transforming Growth Factor Beta 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Genzyme Corp Transforming Growth Factor Beta 1 Product Portfolio
- 4.4.5 Genzyme Corp Recent Developments
- 4.5 Isarna Therapeutics GmbH
- 4.5.1 Isarna Therapeutics GmbH Company Information
- 4.5.2 Isarna Therapeutics GmbH Business Overview
- 4.5.3 Isarna Therapeutics GmbH Transforming Growth Factor Beta 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Isarna Therapeutics GmbH Transforming Growth Factor Beta 1 Product Portfolio
- 4.5.5 Isarna Therapeutics GmbH Recent Developments
- 4.6 Scholar Rock
- 4.6.1 Scholar Rock Company Information
- 4.6.2 Scholar Rock Business Overview
- 4.6.3 Scholar Rock Transforming Growth Factor Beta 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Scholar Rock Transforming Growth Factor Beta 1 Product Portfolio
- 4.6.5 Scholar Rock Recent Developments
- 4.7 Sirnaomics Inc
- 4.7.1 Sirnaomics Inc Company Information
- 4.7.2 Sirnaomics Inc Business Overview
- 4.7.3 Sirnaomics Inc Transforming Growth Factor Beta 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sirnaomics Inc Transforming Growth Factor Beta 1 Product Portfolio
- 4.7.5 Sirnaomics Inc Recent Developments
- 4.8 Eli Lilly and Co
- 4.8.1 Eli Lilly and Co Company Information
- 4.8.2 Eli Lilly and Co Business Overview
- 4.8.3 Eli Lilly and Co Transforming Growth Factor Beta 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli Lilly and Co Transforming Growth Factor Beta 1 Product Portfolio
- 4.8.5 Eli Lilly and Co Recent Developments
- 4.9 Formation Biologics Inc
- 4.9.1 Formation Biologics Inc Company Information
- 4.9.2 Formation Biologics Inc Business Overview
- 4.9.3 Formation Biologics Inc Transforming Growth Factor Beta 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Formation Biologics Inc Transforming Growth Factor Beta 1 Product Portfolio
- 4.9.5 Formation Biologics Inc Recent Developments
- 4.10 Novartis AG
- 4.10.1 Novartis AG Company Information
- 4.10.2 Novartis AG Business Overview
- 4.10.3 Novartis AG Transforming Growth Factor Beta 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novartis AG Transforming Growth Factor Beta 1 Product Portfolio
- 4.10.5 Novartis AG Recent Developments
5 Global Transforming Growth Factor Beta 1 Market Scenario by Region
- 5.1 Global Transforming Growth Factor Beta 1 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Transforming Growth Factor Beta 1 Sales by Region: 2021-2032
- 5.2.1 Global Transforming Growth Factor Beta 1 Sales by Region: 2021-2026
- 5.2.2 Global Transforming Growth Factor Beta 1 Sales by Region: 2027-2032
- 5.3 Global Transforming Growth Factor Beta 1 Revenue by Region: 2021-2032
- 5.3.1 Global Transforming Growth Factor Beta 1 Revenue by Region: 2021-2026
- 5.3.2 Global Transforming Growth Factor Beta 1 Revenue by Region: 2027-2032
- 5.4 North America Transforming Growth Factor Beta 1 Market Facts & Figures by Country
- 5.4.1 North America Transforming Growth Factor Beta 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Transforming Growth Factor Beta 1 Sales by Country (2021-2032)
- 5.4.3 North America Transforming Growth Factor Beta 1 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Transforming Growth Factor Beta 1 Market Facts & Figures by Country
- 5.5.1 Europe Transforming Growth Factor Beta 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Transforming Growth Factor Beta 1 Sales by Country (2021-2032)
- 5.5.3 Europe Transforming Growth Factor Beta 1 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Transforming Growth Factor Beta 1 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Transforming Growth Factor Beta 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Transforming Growth Factor Beta 1 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Transforming Growth Factor Beta 1 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Transforming Growth Factor Beta 1 Market Facts & Figures by Country
- 5.7.1 South America Transforming Growth Factor Beta 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Transforming Growth Factor Beta 1 Sales by Country (2021-2032)
- 5.7.3 South America Transforming Growth Factor Beta 1 Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Transforming Growth Factor Beta 1 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Transforming Growth Factor Beta 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Transforming Growth Factor Beta 1 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Transforming Growth Factor Beta 1 Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Transforming Growth Factor Beta 1 Sales by Type (2021-2032)
- 6.1.1 Global Transforming Growth Factor Beta 1 Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Transforming Growth Factor Beta 1 Sales Market Share by Type (2021-2032)
- 6.2 Global Transforming Growth Factor Beta 1 Revenue by Type (2021-2032)
- 6.2.1 Global Transforming Growth Factor Beta 1 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Transforming Growth Factor Beta 1 Revenue Market Share by Type (2021-2032)
- 6.3 Global Transforming Growth Factor Beta 1 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Transforming Growth Factor Beta 1 Sales by Application (2021-2032)
- 7.1.1 Global Transforming Growth Factor Beta 1 Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Transforming Growth Factor Beta 1 Sales Market Share by Application (2021-2032)
- 7.2 Global Transforming Growth Factor Beta 1 Revenue by Application (2021-2032)
- 7.2.1 Global Transforming Growth Factor Beta 1 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Transforming Growth Factor Beta 1 Revenue Market Share by Application (2021-2032)
- 7.3 Global Transforming Growth Factor Beta 1 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Transforming Growth Factor Beta 1 Value Chain Analysis
- 8.1.1 Transforming Growth Factor Beta 1 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Transforming Growth Factor Beta 1 Production Mode & Process
- 8.2 Transforming Growth Factor Beta 1 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Transforming Growth Factor Beta 1 Distributors
- 8.2.3 Transforming Growth Factor Beta 1 Customers
9 Global Transforming Growth Factor Beta 1 Analyzing Market Dynamics
- 9.1 Transforming Growth Factor Beta 1 Industry Trends
- 9.2 Transforming Growth Factor Beta 1 Industry Drivers
- 9.3 Transforming Growth Factor Beta 1 Industry Opportunities and Challenges
- 9.4 Transforming Growth Factor Beta 1 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst